Beaumont Financial Partners LLC trimmed its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 17.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,296 shares of the biopharmaceutical company’s stock after selling 2,117 shares during the quarter. Beaumont Financial Partners LLC’s holdings in Bristol-Myers Squibb were worth $491,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in BMY. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at about $797,038,000. Oregon Public Employees Retirement Fund boosted its stake in shares of Bristol-Myers Squibb by 2,326.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,230,504 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 8,850,072 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd boosted its stake in shares of Bristol-Myers Squibb by 6,090.3% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 4,130,436 shares of the biopharmaceutical company’s stock valued at $214,700,000 after purchasing an additional 4,063,712 shares in the last quarter. Prudential Financial Inc. boosted its stake in shares of Bristol-Myers Squibb by 90.9% during the fourth quarter. Prudential Financial Inc. now owns 4,967,474 shares of the biopharmaceutical company’s stock valued at $257,891,000 after purchasing an additional 2,365,961 shares in the last quarter. Finally, Ronna Sue Cohen boosted its stake in shares of Bristol-Myers Squibb by 4,702.2% during the first quarter. Ronna Sue Cohen now owns 1,518,227 shares of the biopharmaceutical company’s stock valued at $1,518,000 after purchasing an additional 1,486,612 shares in the last quarter. 77.65% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently issued reports on the company. UBS Group lowered their price objective on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research report on Thursday. Goldman Sachs Group assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price objective for the company. Argus downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 price objective for the company. in a research report on Monday, May 20th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Tuesday, May 7th. Finally, ValuEngine upgraded Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 4th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $56.34.

Shares of BMY opened at $47.56 on Friday. The stock has a market cap of $77.79 billion, a PE ratio of 11.95, a P/E/G ratio of 2.21 and a beta of 0.74. The company has a quick ratio of 1.79, a current ratio of 1.93 and a debt-to-equity ratio of 0.37. Bristol-Myers Squibb Co has a 1 year low of $44.30 and a 1 year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. The business had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.72 billion. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.94 earnings per share. On average, research analysts anticipate that Bristol-Myers Squibb Co will post 4.18 EPS for the current fiscal year.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 5,000 shares of the stock in a transaction on Thursday, May 16th. The stock was acquired at an average cost of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the acquisition, the director now owns 27,000 shares in the company, valued at approximately $1,276,830. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the sale, the insider now owns 3,066 shares of the company’s stock, valued at $145,818.96. The disclosure for this sale can be found here. Insiders own 0.12% of the company’s stock.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/beaumont-financial-partners-llc-sells-2117-shares-of-bristol-myers-squibb-co-nysebmy/3042949.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.